Login
Toggle navigation
Videos
Categories
Trending
Flash is missing. Download it from
Adobe
.
Invests, and empowers viable blockchain entrepreneurs, startups, and communities|Yi He,Co-Founder and Head of Ventures,Binance Labs
00:10:00
Watch Full Video
×
Please Login to watch Full video
Login
+ ADD TO Wishlist
×
Please login
Login
Share On Facebook
Share On Twitter
Co-founder and CMO at Binance.
Recent Videos
00:10:00
Dryden Gold Secures $20M+ War Chest, Delivers High-Grade Discoveries and Expands Drill Targets Across Gold Rock District|Trey Wasser,CEO & Director,Dryden Gold
00:10:00
Mitchell Services Targets $50–60M EBITDA as Rig Utilization Drives Earnings Upside| Andrew Elf,CEO,Mitchell Services Limited
00:10:00
Lomiko Metals Reports Strong Pre-Feasibility Results with $800M NPV, Advancing High-Growth Graphite Projects|Gordana Slepcev,CEO,Lomiko Metals Inc.4
00:10:00
Generative AI Meets Wet Lab: Absci Accelerates Biologic Development with Hybrid Business Model|Sean McClain,CEO,Absci
00:10:00
Obliva Aims to Transform Lives of Children with Rare Mitochondrial Disorders|Ellen K. Donnelly ,CEO,Abliva AB7
00:10:00
Abionic Repositions Bio-HDL Therapy CCR001 for Rare Kidney and Eye Disorders with Promising Early Results|Cyrille Tupin,CEO,ABIONYX Pharma
00:10:00
Abingdon Health Reports 45% H1 Revenue Growth Amid Strategic Expansion and Large Contract Wins|Dr Chris Hand,Chairman,Abingdon Health
00:10:00
EB-101 Gene Therapy Shows Promising Results in Treating Recessive Dystrophic EB|Vishwas Seshadri,CEO,Abeona Therapeutics
00:10:00
Revolutionizing Trauma Care: How AAP’s Silver Technology is Fighting Deadly Implant Infections|Rubino Di Girolamo,CEO,aap Implantate AG
00:10:00
Revolutionizing Cancer Treatment: Tumor-Agnostic mTOR Targeting Shows Breakthrough Success in Rare and Genetic-Driven Tumors| Neil Desai, Founder, Executive Chairman ,Aadi Bioscience
00:10:00
Millions Affected, No Approved Cure: 89bio Advances New Therapy for NASH|Rohan Palekar,CEO,89bio Inc2
00:10:00
Malaria Prevention Drug Arakoda Positioned to Drive Future Growth for 60 Degrees Pharmaceuticals|Geoffrey Dow,President,60 Degrees Pharmaceuticals
00:10:00
4DMedical Revolutionizes Lung Imaging with CTVQ: Turning a Simple CT Scan into Functional Lung Diagnostics|Dr Andreas Fouras,CEO,4Dmedical Ltd
00:10:00
4DMedical Revolutionizes Lung Imaging with CTVQ: Turning a Simple CT Scan into Functional Lung Diagnostics|Dr Andreas Fouras,CEO,4Dmedical Ltd
00:10:00
4basebio CEO Heikki Lanckriet Unveils Vision for Next-Generation Synthetic DNA and Gene Therapy Components|Heikki Lanckriet,CEO,4basebio
00:10:00
Jim Woody on Leading 180 Life Sciences: Advancing Breakthrough Biologic Therapies for Inflammation, Fibrosis, and Pain|Dr. Jim Woody,CEO,180 Life Sciences
Suggestions
00:10:00
Strategic Plan and Risks for Wealth Management and Capital Allocation
00:10:00
Expanding Horizons: Bhanu Singh on Dimensional’s Active ETF Launch in Australia | Bhanu Singh - CEO, Dimensional Funds Australia
00:10:00
Angela Durant on Nickel: Defying Supply and Demand in 2020
00:10:00
Aashish Somaiya: Champion of Probabilistic Investing at Whiteoak Capital
00:10:00
Exclusive Interview with President & CEO Tim Heenan and Chairman Patrick Evans | Tim Heenan - PRESIDENT, CEO & DIRECTOR of Mirasol Resources Ltd.
00:10:00
startup founders and aspiring entrepreneurs learn, connect, and build their businesses.|Mark Suster,General Partner,Upfront Ventures
00:00:00
Evgen Pharma talks through clinical milestones and financial results from its 2022 full year report - Huw Jones, CEO, Evgen Pharma
00:10:00
From Intel Intern to Food Tech Visionary: Funding, Challenges|Brian Frank,General Partner,FTW Ventures
00:10:00
Brown Wealth Management: Legacy Planning and Heritage Design | Timothy Brown - President of Brown Wealth Management, LLC
00:10:00
Interview with Forensics Expert David Brookman on Tucson Means Business
00:10:00
The Last Honest Man: Frank Church's Legacy in Defending Democracy|James Risen, Professor,University of Maryland's Philip Merrill College of Journalism
00:10:00
SUPERIOR SAFETY PROFILE WITH MINIMAL SIDE EFFECTS|JOHN CAVAN,CEO,ContraVir Pharmaceuticals Inc